

# VEGF R2/KDR

Catalog # PVGS1826

## Product Information

---

<b>Primary Accession Species</b>	<a href="#">P35968-1</a> Human
<b>Sequence</b>	Ala20-Glu764
<b>Purity</b>	> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
<b>Endotoxin Level</b>	Less than 1EU per $\mu$ g by the LAL method.
<b>Biological Activity</b>	Immobilized Human VEGF165, No Tag at 5 $\mu$ g/ml (100 $\mu$ l/Well) on the plate can bind VEGF R2/KDR[Biotin] mFc Chimera, Human (Cat.No.: Z03972)
<b>Expression System</b>	HEK293
<b>Theoretical Molecular Weight</b>	110 kDa
<b>Formulation</b>	Lyophilized from a 0.22 $\mu$ m filtered solution in PBS, (pH 7.4).
<b>Reconstitution</b>	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O more than 100 $\mu$ g/ml.
<b>Storage &amp; Stability</b>	Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

## Additional Information

---

<b>Target Background</b>	Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.
--------------------------	--

## Protein Information

---

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.